ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

ARAV Company Profile and Key Details

NASDAQ : ARAV

Aravive, Inc.

$0.04

-0.0062-13.39%

At Close 4:00 PM

Not Actively Trading

69.72

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

ARAV Stock Price Chart

no data

Stock Price Today

Aravive, Inc. (ARAV) stock declined over -13.39%, trading at $0.04 on NASDAQ, down from the previous close of $0.05. The stock opened at $0.04, fluctuating between $0.04 and $0.05 in the recent session.

Stock Snapshot

0.0463

Prev. Close

0.04

Open

2.95M

Market Cap

73.56M

Number of Shares

0.0401

Day Low

0.046

Day High

-0.052763157894736845

P/E Ratio

61.28%

Free Float in %

-0.76

EPS (TTM)

0.02

Book Value

-0.78

Cash Flow per Share

4.04M

Volume

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 07, 2024	0.04	0.04	0.04	0.04	0
Feb 06, 2024	0.04	0.04	0.04	0.04	0
Feb 05, 2024	0.04	0.04	0.04	0.04	0
Feb 02, 2024	0.04	0.04	0.04	0.04	0
Feb 01, 2024	0.04	0.04	0.04	0.04	0
Jan 31, 2024	0.04	0.04	0.04	0.04	0
Jan 30, 2024	0.04	0.04	0.04	0.04	0
Jan 29, 2024	0.04	0.04	0.04	0.04	0
Jan 26, 2024	0.04	0.05	0.04	0.04	4.04M
Jan 25, 2024	0.05	0.05	0.04	0.05	3.46M
Jan 24, 2024	0.04	0.05	0.04	0.05	5.08M
Jan 23, 2024	0.05	0.05	0.04	0.04	6.49M
Jan 22, 2024	0.05	0.05	0.05	0.05	4.11M
Jan 19, 2024	0.05	0.06	0.05	0.05	8.63M
Jan 18, 2024	0.05	0.07	0.05	0.06	24.01M
Jan 17, 2024	0.11	0.11	0.11	0.11	5.56M
Jan 16, 2024	0.12	0.12	0.11	0.11	1.55M
Jan 12, 2024	0.12	0.13	0.11	0.12	4.1M
Jan 11, 2024	0.11	0.12	0.11	0.11	3.81M
Jan 10, 2024	0.12	0.12	0.11	0.11	959.49K

Contact Details

Houston, TX 77098

United States

Website: https://aravive.comContact: 936 355 1910

About Company

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Frequently Asked Questions

What is the current Aravive, Inc. (ARAV) stock price?

Aravive, Inc. (NASDAQ: ARAV) stock price is $0.04 in the last trading session. During the trading session, ARAV stock reached the peak price of $0.05 while $0.04 was the lowest point it dropped to. The percentage change in ARAV stock occurred in the recent session was -13.39% while the dollar amount for the price change in ARAV stock was -$0.01.

ARAV's industry and sector of operation?

The NASDAQ listed ARAV is part of Biotechnology industry that operates in the broader Healthcare sector. Aravive, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ARAV?

Dr. Fredric N. Eshelman Pharm.D.
Executive Chairman
Dr. Gail F. McIntyre CH (ASCP), DABT, Ph.D.
Pres, Chief Executive Officer & Director
Dr. Randy L. Anderson
Senior Vice President of Data Sciences
Dr. Robert B. Geller M.D.
Chief Medical Officer
Ms. Carolina Petrini
Chief Commercial Officer
Dr. Jeffrey L. Cleland Ph.D.
Co-Founder
Dr. Joshua Silverman Ph.D.
Co-Founder
Mr. Marek Ciszewski J.D.
Senior Vice President of Investor Relations
Mr. Rudy C. Howard B.A., CPA, CPA
Chief Financial Officer
Dr. Leonard Scott Dove Ph.D.
Chief Operating Officer
Kenneth L. Guernsey
Sec.

How ARAV did perform over past 52-week?

ARAV's closing price is 0.25% higher than its 52-week low of $0.04 where as its distance from 52-week high of $2.46 is -98.37%.

How many employees does ARAV have?

Number of ARAV employees currently stands at 23.

Link for ARAV official website?

Official Website of ARAV is: https://aravive.com

How do I contact ARAV?

ARAV could be contacted at phone 936 355 1910 and can also be accessed through its website. ARAV operates from River Oaks Tower, Houston, TX 77098, United States.

How many shares of ARAV are traded daily?

ARAV stock volume for the day was 4.04M shares. The average number of ARAV shares traded daily for last 3 months was 2.24M.

What is the market cap of ARAV currently?

The market value of ARAV currently stands at $2.95M with its latest stock price at $0.04 and 73.56M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Employees	23
Beta	2.19
Sales or Revenue	$9.14M
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology